A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

As with any anticoagulant, factor Xa (FXa) inhibitors are associated with a risk of major bleeding. Andexanet alfa is a recombinant modified human FXa lacking enzymatic activity, developed for reversal of FXa inhibitor–induced anticoagulation. In two phase 2, randomized, double-blind, placebo-contro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Lu, Genmin, Conley, Pamela B., Leeds, Janet M., Karbarz, Mark J., Levy, Gallia G., Mathur, Vandana S., Castillo, Janice, Crowther, Mark, Curnutte, John T.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Thrombosis and Hemostasis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042988/
https://ncbi.nlm.nih.gov/pubmed/32092140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000885
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars